Reporting and enrollment disparities in hematologic malignancy trials between 2000–2023

Y. Gong, Inna; Rafinejad‐Farahani, Bahar; Majeed, Haris; J. Soto, Mark; M. Oza, Amit; Ehrlich, Tali; Fernandez Lynch, Holly; E. Guerra, Carmen; Lofters, Aïsha; M. Unger, Joseph; M. Conti, Rena; B. Rosenthal, Meredith; Rodin, Danielle

doi:10.1080/10428194.2025.2579735

Public

Reporting and enrollment disparities in hematologic malignancy trials between 2000–2023

Published in Leukemia & lymphoma/Leukemia and lymphoma • Nov 3, 2025

Authors:

Inna Y. Gong

Bahar Rafinejad‐Farahani

Haris Majeed

Abstract

Despite initiatives to enhance diversity in clinical trials (CTs), disparities persist in hematologic malignancy (HM) studies. We reviewed 1,230 US-based phase II-III HM CTs (2000-2023) including 149,434 participants and compared enrollment to SEER benchmarks. Race was reported in 59% of trials and ...

Subject

Medicine

Hematologic malignancy

Clinical trial

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!